Cure8 research brief
The T&W criteria are still used to define severe UC on admission, but relying on them alone may delay recognition of steroid non‑response and escalation decisions. Integrating biomarkers, endoscopy, and imaging can help identify high risk earlier and inform timely treatment or surgery decisions.
Clinicians managing ASUC; gastroenterology researchers; adult patients and caregivers interested in inpatient IBD care.
This opinion piece reviews the historical role of the Truelove and Witts (T&W) criteria for defining acute severe ulcerative colitis (ASUC) and argues they should remain an entry definition for classic ASUC but not be used alone for dynamic risk stratification or treat‑to‑target decisions.
The authors note contemporary practice increasingly pairs bedside clinical toxicity assessment with objective biomarkers (CRP, albumin, fecal calprotectin), validated endoscopic scoring, and imaging such as intestinal ultrasound to identify steroid non‑response earlier and guide escalation of therapy.
They recommend future severity classifications integrate clinical signs with biomarkers, endoscopy, and imaging and be prospectively validated across different resource settings. This is an expert/opinion article (abstract-level summary) rather than original trial data; it summarizes trends in guidelines and argues for a reframing of ASUC assessment.
Opinion/abstract-level piece summarizing guideline trends; not primary trial data. Calls for prospective validation across resource settings.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
People with IBD who have no or few symptoms but still have moderate–severe inflammation on endoscopy face uncertainty about whether to switch therapies to aim for endoscopic remission.
Noninvasive monitoring matters for children with UC because endoscopy is burdensome. If ultrasound (and simple measures like bowel wall thickness) can reliably detect moderate-to-severe disease, families may avoid some...
Noninvasive blood biomarkers that track IBD activity could reduce reliance on repeat endoscopy. If validated, serum galectin‑3 might complement fecal calprotectin and CRP to help identify active disease.
